Lauren K Truby1, A Reshad Garan1, Raymond C Givens1, Koji Takeda1, Hiroo Takayama1, Pauline N Trinh1, Melana Yuzefpolskaya1, Maryjane A Farr1, Yoshifumi Naka1, Paolo C Colombo1, Veli K Topkara2. 1. Division of Cardiology, Department of Medicine (L.K.T., A.R.G., R.C.G., P.N.T., M.Y., M.A.F., P.C.C., V.K.T.), and Division of Cardiothoracic Surgery, Department of Surgery (K.T., H.T., Y.N.), Columbia University College of Physicians and Surgeons, New York, NY. 2. Division of Cardiology, Department of Medicine (L.K.T., A.R.G., R.C.G., P.N.T., M.Y., M.A.F., P.C.C., V.K.T.), and Division of Cardiothoracic Surgery, Department of Surgery (K.T., H.T., Y.N.), Columbia University College of Physicians and Surgeons, New York, NY. vt2113@cumc.columbia.edu.
Abstract
BACKGROUND: Continuous-flow left ventricular assist devices (CF-LVADs) have become a standard treatment choice in advanced heart failure patients. We hypothesized that practice patterns with regards to CF-LVAD utilization vary significantly among transplant centers and impact waitlist outcomes. METHODS AND RESULTS: The United Network for Organ Sharing registry was queried to identify adult patients who were waitlisted for heart transplantation (HT) between 2008 and 2015. Each patient was assigned a propensity score based on likelihood of receiving a durable CF-LVAD before or while waitlisted. The primary outcomes of interest were death or delisting for worsening status and HT at 1 year. A total of 22 863 patients from 92 centers were identified. Among these, 9013 (39.4%) were mechanically supported. CF-LVAD utilization varied significantly between and within United Network for Organ Sharing regions. Freedom from waitlist death or delisting was significantly lower in propensity-score-matched patients who were mechanically supported versus medically managed (83.5% versus 79.2%; P<0.001). However, cumulative incidence of HT was also lower in mechanically supported patients (53.3% versus 63.6%; P<0.001). Congruous mechanical and medical bridging strategies based on clinical risk profile were associated with lower risk of death or delisting (hazard ratio, 0.88; P=0.027) and higher likelihood of HT (hazard ratio, 1.14; P<0.001). CONCLUSIONS: CF-LVAD utilization may lower waitlist mortality at the expense of lower likelihood of HT. Decision to use CF-LVAD and timing of transition should be individualized based on patient-, center-, and region-level risk factors to achieve optimal outcomes.
BACKGROUND: Continuous-flow left ventricular assist devices (CF-LVADs) have become a standard treatment choice in advanced heart failurepatients. We hypothesized that practice patterns with regards to CF-LVAD utilization vary significantly among transplant centers and impact waitlist outcomes. METHODS AND RESULTS: The United Network for Organ Sharing registry was queried to identify adult patients who were waitlisted for heart transplantation (HT) between 2008 and 2015. Each patient was assigned a propensity score based on likelihood of receiving a durable CF-LVAD before or while waitlisted. The primary outcomes of interest were death or delisting for worsening status and HT at 1 year. A total of 22 863 patients from 92 centers were identified. Among these, 9013 (39.4%) were mechanically supported. CF-LVAD utilization varied significantly between and within United Network for Organ Sharing regions. Freedom from waitlist death or delisting was significantly lower in propensity-score-matched patients who were mechanically supported versus medically managed (83.5% versus 79.2%; P<0.001). However, cumulative incidence of HT was also lower in mechanically supported patients (53.3% versus 63.6%; P<0.001). Congruous mechanical and medical bridging strategies based on clinical risk profile were associated with lower risk of death or delisting (hazard ratio, 0.88; P=0.027) and higher likelihood of HT (hazard ratio, 1.14; P<0.001). CONCLUSIONS:CF-LVAD utilization may lower waitlist mortality at the expense of lower likelihood of HT. Decision to use CF-LVAD and timing of transition should be individualized based on patient-, center-, and region-level risk factors to achieve optimal outcomes.
Authors: E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: James K Kirklin; David C Naftel; Robert L Kormos; Lynne W Stevenson; Francis D Pagani; Marissa A Miller; Karen L Ulisney; J Timothy Baldwin; James B Young Journal: J Heart Lung Transplant Date: 2011-02 Impact factor: 10.247
Authors: Mark S Slaughter; Francis D Pagani; Edwin C McGee; Emma J Birks; William G Cotts; Igor Gregoric; O Howard Frazier; Timothy Icenogle; Samer S Najjar; Steven W Boyce; Michael A Acker; Ranjit John; David R Hathaway; Kevin B Najarian; Keith D Aaronson Journal: J Heart Lung Transplant Date: 2013-07 Impact factor: 10.247
Authors: Lars H Lund; Leah B Edwards; Anne I Dipchand; Samuel Goldfarb; Anna Y Kucheryavaya; Bronwyn J Levvey; Bruno Meiser; Joseph W Rossano; Roger D Yusen; Josef Stehlik Journal: J Heart Lung Transplant Date: 2016-08-21 Impact factor: 10.247
Authors: Omar Wever-Pinzon; Stavros G Drakos; Abdallah G Kfoury; Jose N Nativi; Edward M Gilbert; Melanie Everitt; Rami Alharethi; Kim Brunisholz; Feras M Bader; Dean Y Li; Craig H Selzman; Josef Stehlik Journal: Circulation Date: 2012-12-27 Impact factor: 29.690
Authors: James K Kirklin; David C Naftel; Robert L Kormos; Lynne W Stevenson; Francis D Pagani; Marissa A Miller; Karen L Ulisney; J Timothy Baldwin; James B Young Journal: J Heart Lung Transplant Date: 2010-01 Impact factor: 10.247
Authors: Leslie W Miller; Francis D Pagani; Stuart D Russell; Ranjit John; Andrew J Boyle; Keith D Aaronson; John V Conte; Yoshifumi Naka; Donna Mancini; Reynolds M Delgado; Thomas E MacGillivray; David J Farrar; O H Frazier Journal: N Engl J Med Date: 2007-08-30 Impact factor: 91.245
Authors: Jaimin R Trivedi; Allen Cheng; Ramesh Singh; Matthew L Williams; Mark S Slaughter Journal: Ann Thorac Surg Date: 2014-07-31 Impact factor: 4.330
Authors: Brittney H Davis; Chrisly Dillon; Anping Cai; Lance A Williams Iii; Salpy V Pamboukian; Nita A Limdi Journal: Pharmacogenomics Date: 2019-05 Impact factor: 2.533
Authors: Lauren K Truby; Maryjane A Farr; A Reshad Garan; Raymond Givens; Susan W Restaino; Farhana Latif; Hiroo Takayama; Yoshifumi Naka; Koji Takeda; Veli K Topkara Journal: Circulation Date: 2019-06-17 Impact factor: 29.690
Authors: John H Yazji; Pankaj Garg; Ishaq Wadiwala; Mohammad Alomari; Emad Alamouti-Fard; Md Walid Akram Hussain; Samuel Jacob Journal: Cureus Date: 2022-05-30
Authors: William F Parker; Allen S Anderson; Robert D Gibbons; Edward R Garrity; Lainie F Ross; Elbert S Huang; Matthew M Churpek Journal: JAMA Date: 2019-11-12 Impact factor: 56.272
Authors: Veli K Topkara; Kevin J Clerkin; Justin A Fried; Jan Griffin; Jayant Raikhelkar; Sun Hi Lee; Farhana Latif; Marlena Habal; Evelyn Horn; Maryjane A Farr; Koji Takada; Yoshifumi Naka; Ulrich P Jorde; Gabriel Sayer; Nir Uriel Journal: Circ Heart Fail Date: 2021-05-28 Impact factor: 10.447
Authors: Olivia S Kates; Cynthia E Fisher; Robert M Rakita; Jorge D Reyes; Ajit P Limaye Journal: Am J Transplant Date: 2020-06-11 Impact factor: 9.369
Authors: S Roest; S E Kaffka Genaamd Dengler; V van Suylen; N P van der Kaaij; K Damman; L W van Laake; J A Bekkers; M Dalinghaus; M E Erasmus; O C Manintveld Journal: Neth Heart J Date: 2020-11-06 Impact factor: 2.380